AT552848T - Method and compositions with supramolecular constructs - Google Patents

Method and compositions with supramolecular constructs

Info

Publication number
AT552848T
AT552848T AT05723323T AT05723323T AT552848T AT 552848 T AT552848 T AT 552848T AT 05723323 T AT05723323 T AT 05723323T AT 05723323 T AT05723323 T AT 05723323T AT 552848 T AT552848 T AT 552848T
Authority
AT
Austria
Prior art keywords
compositions
method
supramolecular constructs
supramolecular
constructs
Prior art date
Application number
AT05723323T
Other languages
German (de)
Inventor
Claude Yves Nicolau
Ruth Greferath
David Hickman
Original Assignee
Ac Immune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US10/783,975 priority Critical patent/US20040242845A1/en
Priority to US10/958,211 priority patent/US8663650B2/en
Application filed by Ac Immune Sa filed Critical Ac Immune Sa
Priority to PCT/US2005/005285 priority patent/WO2005081872A2/en
Publication of AT552848T publication Critical patent/AT552848T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0007Nervous system antigens; Prions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
AT05723323T 2003-02-21 2005-02-22 Method and compositions with supramolecular constructs AT552848T (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/783,975 US20040242845A1 (en) 2003-02-21 2004-02-20 Methods and compositions comprising supramolecular antigenic constructs and antibodies elicited against them
US10/958,211 US8663650B2 (en) 2003-02-21 2004-10-04 Methods and compositions comprising supramolecular constructs
PCT/US2005/005285 WO2005081872A2 (en) 2004-02-20 2005-02-22 Methods and compositions comprising supramolecular constructs

Publications (1)

Publication Number Publication Date
AT552848T true AT552848T (en) 2012-04-15

Family

ID=34915784

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05723323T AT552848T (en) 2003-02-21 2005-02-22 Method and compositions with supramolecular constructs

Country Status (9)

Country Link
US (3) US8663650B2 (en)
EP (2) EP2465533B1 (en)
JP (1) JP2011251964A (en)
KR (1) KR101208173B1 (en)
CN (1) CN101420983B (en)
AT (1) AT552848T (en)
AU (1) AU2005216100B2 (en)
CA (1) CA2556479C (en)
WO (1) WO2005081872A2 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
NZ579310A (en) 2007-03-01 2012-03-30 Probiodrug Ag Use of glutaminyl cyclase inhibitors for the treatment of mild cognitive impairment and diagnostic purposes thereof
US20080026995A1 (en) * 2003-07-25 2008-01-31 Ac Immune Sa Therapeutic vaccine targeted against p-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
FR2857875A1 (en) * 2003-07-25 2005-01-28 Univ Reims Champagne Ardenne Immunogenic composition containing fatty acid-modified peptides from protein P-170, useful e.g. for reversing multidrug resistance of cancer cells
US7807171B2 (en) * 2003-07-25 2010-10-05 Ac Immune Sa Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
AU2007340343A1 (en) * 2006-09-05 2008-07-10 Medivas, Llc Polymer-stabilized liposomal compositions and methods of use
AU2006320392B2 (en) 2005-11-30 2013-01-17 AbbVie Deutschland GmbH & Co. KG Monoclonal antibodies against amyloid beta protein and uses thereof
ES2524984T3 (en) 2005-11-30 2014-12-16 Abbvie Inc. Anti-globulomer antibodies to? Antigen-binding portions thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods for producing said antibodies, compositions comprising said antibodies, uses of said antibodies, and methods for using said antibodies
EP2038310B1 (en) * 2006-07-12 2010-06-09 Novartis AG Actinically crosslinkable copolymers for manufacturing contact lenses
EP2046833B9 (en) 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
NZ601843A (en) * 2007-06-12 2014-01-31 Ac Immune Sa Monoclonal anti beta amyloid antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
EP2149380A1 (en) * 2008-07-29 2010-02-03 Medivet Pharma, S.L. Veterinary immunotherapy compositions for the Aged Related Cognitive Dysfunction.
CA2755683A1 (en) * 2009-03-18 2010-09-23 Ac Immune S.A. Method for therapeutic use
SG175037A1 (en) * 2009-04-03 2011-11-28 Ac Immune Sa Pharmaceutical composition
EA022007B1 (en) 2009-09-11 2015-10-30 Пробиодруг Аг Heterocylcic derivatives as inhibitors of glutaminyl cyclase
EP2538982A4 (en) 2010-02-25 2016-02-17 Janssen Alzheimer Immunotherap Pet monitoring of ab-directed immunotherapy
ES2586231T3 (en) 2010-03-03 2016-10-13 Probiodrug Ag Glutaminyl cyclase inhibitors
CN102791704B (en) 2010-03-10 2015-11-25 前体生物药物股份公司 Glutaminyl cyclase (qc, ec 2.3.2.5) heterocyclic inhibitors
CA2796339A1 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
JP5945532B2 (en) 2010-04-21 2016-07-05 プロビオドルグ エージー Benzimidazole derivatives as inhibitors of glutaminyl cyclase
EP2598882B1 (en) 2010-07-30 2017-07-26 AC Immune S.A. Safe and functional humanized antibodies for use in treating an amyloidosis
EP3527220A1 (en) * 2010-08-12 2019-08-21 AC Immune S.A. Vaccine engineering
CA2808187A1 (en) 2010-08-14 2012-02-23 Abbvie Inc. Amyloid-beta binding proteins
AU2011322553B2 (en) * 2010-10-26 2015-07-02 Ac Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
DK2686313T3 (en) 2011-03-16 2016-05-02 Probiodrug Ag Benzimidazole derivatives as inhibitors of glutaminyl cyclase
KR20160005380A (en) 2011-09-23 2016-01-15 에이씨 이뮨 에스.에이. Vaccine therapy
SG11201406347TA (en) 2012-04-05 2014-11-27 Ac Immune Sa Humanized tau antibody
WO2014150877A2 (en) 2013-03-15 2014-09-25 Ac Immune S.A. Anti-tau antibodies and methods of use
EP3461819A1 (en) 2017-09-29 2019-04-03 Probiodrug AG Inhibitors of glutaminyl cyclase

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4565696A (en) 1983-08-03 1986-01-21 The Regents Of The University Of California Production of immunogens by antigen conjugation to liposomes
AT72123T (en) 1985-04-19 1992-02-15 Wistar Inst An immunogenic vaccine against a virus schuetzenden T cell response for the generation.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5434050A (en) * 1991-08-13 1995-07-18 Regents Of The University Of Minnesota Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
US5837822A (en) 1992-01-27 1998-11-17 Icos Corporation Humanized antibodies specific for ICAM related protein
US5243931A (en) * 1992-06-11 1993-09-14 Mcdonough Richard W Pet grooming restraint device
IT1257893B (en) 1992-06-17 1996-02-16 Ist Superiore Sanita Monoclonal antibodies that recognize an epitope of human P-glycoprotein.
WO1994010198A1 (en) 1992-11-02 1994-05-11 Yves Claude Nicolau Method of reducing multidrug resistance in cells and tissues
US20040248799A1 (en) 1993-05-27 2004-12-09 Holaday John W. Compositions and methods for treating cancer and hyperproliferative disorders
CA2137297C (en) 1993-12-06 2000-04-18 Tsuyoshi Miyazaki Reactive vesicle and functional substance-fixed vesicle
JP3759759B2 (en) 1994-03-04 2006-03-29 日本油脂株式会社 Liposomes and drug carriers
US5885613A (en) * 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
CU22545A1 (en) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtaining a chimeric antibody and humanized against the receptor for epidermal growth factor diagnostic and therapeutic use
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US6521211B1 (en) * 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5662069A (en) * 1995-09-21 1997-09-02 Smith; Leonard Animal bathing apparatus
CN1196785C (en) 1997-04-16 2005-04-13 惠氏 Beta-amyloid peptdie-binding proteins and polynucleotides encoding the same
KR19990029749A (en) 1997-09-17 1999-04-26 미우라 아끼라 Complexes containing divalent derivative thereof and a reactive water-soluble polymer
JP4385152B2 (en) 1997-09-17 2009-12-16 三菱化学株式会社 Bivalent reactive water-soluble polymer derivative and complex containing the same
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6187335B1 (en) 1997-12-31 2001-02-13 Orasomal Technologies, Inc. Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom
WO1999041279A2 (en) 1998-02-13 1999-08-19 Arch Development Corporation Methods and compositions comprising the use of blocked b-amyloid peptide
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6025160A (en) 1998-07-22 2000-02-15 Smithkline Beecham Corporation Polynucleotide and polypeptide sequences encoding rat mdr1b2 and screening methods thereof
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
EP1185296B1 (en) 1999-06-01 2011-01-19 Neotope Biosciences Limited Prevention and treatment of amyloidogenic diseases
AT461996T (en) 1999-09-03 2010-04-15 Univ Ramot Compounds, compositions and methods for the treatment or prevention of alzheimer disease
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US7442776B2 (en) 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
IL149924D0 (en) 1999-11-29 2002-11-10 Neurochem Inc Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
US20020094335A1 (en) 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
AU781729B2 (en) 1999-12-22 2005-06-09 Nektar Therapeutics Method for the preparation of 1-benzotriazolyl carbonate esters of poly(ethylene glycol)
IT1307309B1 (en) 1999-12-30 2001-10-30 Enea Ente Nuove Tec Stabilizing peptides, polypeptides and antibodies that include them.
US6521635B1 (en) 2000-01-20 2003-02-18 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of MXR transport by acridine derivatives
US20030086938A1 (en) 2000-02-21 2003-05-08 Jensen Martin Roland Novel methods for down-regulation of amyloid
AU4178601A (en) 2000-02-24 2001-09-03 Univ Washington Humanized antibodies that sequester abeta peptide
AU2001249760B2 (en) 2000-03-30 2005-04-21 Dyax Corp. Mucin-1 specific binding members and methods of use thereof
JP2002047298A (en) 2000-07-10 2002-02-12 Academia Sinica New anticancer agent transfer system
CA2418036A1 (en) 2000-07-31 2002-02-07 Yale University Innate immune system-directed vaccines
EP2305822A3 (en) 2000-09-06 2013-11-06 Aventis Pharma S.A. Methods and compositions for diseases associated with Amyloidosis
US6669933B2 (en) 2001-05-10 2003-12-30 Revlon Consumer Products Corporation Method and compositions for coloring hair
DE50103881D1 (en) 2001-06-12 2004-11-04 Wiltfang Jens A monoclonal antibody 1E8 mbAb, which is specific for the first two N-terminal amino acids of beta-amyloid peptides and the use thereof for the detection of amyloid beta peptides and / or sAPPa
EP1397380B1 (en) 2001-06-20 2006-12-27 Ramot at Tel Aviv University Ltd. Multiple antigenic peptide displaying multiple copies of an epitope of a plaque-forming polypeptide and methods of using same
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
US7060270B2 (en) 2001-11-02 2006-06-13 Diagenics International Corporation Methods and compositions of monoclonal antibodies specific for beta-amyloid proteins
EP1806364B1 (en) 2002-01-18 2013-07-31 Pierre Fabre Medicament New anti-IGF-IR antibodies and their applications
AR038568A1 (en) 2002-02-20 2005-01-19 Hoffmann La Roche Anti-beta and its use
US20080233181A1 (en) 2002-04-12 2008-09-25 Nagy Jon O Nanoparticle adjuvants for sub-unit vaccines
WO2004013172A2 (en) 2002-07-24 2004-02-12 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
AU2003298787A1 (en) 2002-11-27 2004-06-23 Gtc Biotherapeutics, Inc. Modified antibodies stably produced in milk and methods of producing same
CA2513722A1 (en) 2003-02-01 2004-08-19 Neuralab Limited Active immunization to generate antibodies to soluble a-beta
ES2344645T3 (en) 2003-02-10 2010-09-02 Applied Molecular Evolution, Inc. Molecules of union to abeta.
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US20040242845A1 (en) 2003-02-21 2004-12-02 Nicolau Yves Claude Methods and compositions comprising supramolecular antigenic constructs and antibodies elicited against them
JP2007500218A (en) 2003-05-12 2007-01-11 アフィーマックス・インコーポレイテッドAffymax, Inc. New spacer moiety of poly (ethylene glycol) modified peptide compounds
US7807171B2 (en) 2003-07-25 2010-10-05 Ac Immune Sa Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
FR2857875A1 (en) 2003-07-25 2005-01-28 Univ Reims Champagne Ardenne Immunogenic composition containing fatty acid-modified peptides from protein P-170, useful e.g. for reversing multidrug resistance of cancer cells
US20080026995A1 (en) 2003-07-25 2008-01-31 Ac Immune Sa Therapeutic vaccine targeted against p-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
US20050255561A1 (en) 2003-07-25 2005-11-17 Pierre-Francois Tosi Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
US20050244419A1 (en) 2003-07-25 2005-11-03 Pierre-Francois Tosi Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
US20040260068A1 (en) 2004-02-26 2004-12-23 Naoya Tsurushita Humanized chicken antibodies
US7763249B2 (en) 2004-04-27 2010-07-27 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human anti-amyloid β peptide antibody and fragment of said antibody
NZ554725A (en) 2004-10-25 2009-10-30 Merck & Co Inc Anti-ADDL antibodies and uses thereof
AR051800A1 (en) 2004-12-15 2007-02-07 Wyeth Corp Beta antibodies used to improve cognition
AU2005316503A1 (en) 2004-12-17 2006-06-22 Dynavax Technologies Corporation Methods and compositions for induction or promotion of immune tolerance
DK2074145T5 (en) 2006-10-02 2017-10-16 Ac Immune Sa Humanized antibody against amyloid beta
JP5419131B2 (en) 2005-12-12 2014-02-19 エーシー イミューン ソシエテ アノニム Β1-42 specific monoclonal antibodies with therapeutic properties
EP2046833B9 (en) 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
SG175037A1 (en) 2009-04-03 2011-11-28 Ac Immune Sa Pharmaceutical composition

Also Published As

Publication number Publication date
KR101208173B1 (en) 2013-01-14
US20070281006A1 (en) 2007-12-06
CA2556479C (en) 2016-04-26
CN101420983A (en) 2009-04-29
WO2005081872A3 (en) 2009-04-09
AU2005216100A1 (en) 2005-09-09
US20060073158A1 (en) 2006-04-06
US20120045463A9 (en) 2012-02-23
CN101420983B (en) 2013-04-17
EP1763364A4 (en) 2009-09-30
EP1763364A2 (en) 2007-03-21
US8926983B2 (en) 2015-01-06
AU2005216100B2 (en) 2010-04-29
WO2005081872A2 (en) 2005-09-09
US8663650B2 (en) 2014-03-04
EP1763364B1 (en) 2012-04-11
JP2011251964A (en) 2011-12-15
US20150183857A1 (en) 2015-07-02
EP2465533A1 (en) 2012-06-20
CA2556479A1 (en) 2005-09-09
US9975946B2 (en) 2018-05-22
EP2465533B1 (en) 2015-03-25
KR20060134110A (en) 2006-12-27
EP1763364B9 (en) 2013-07-03

Similar Documents

Publication Publication Date Title
DK1715903T3 (en) injecting
DK1755713T3 (en) injecting
DK1755706T3 (en) injecting
DK1755709T3 (en) injecting
DK1755708T3 (en) injecting
DK1753490T3 (en) injecting
DK1732968T3 (en) Binder compositions and associated methods
DK1812076T3 (en) Platelet-derived growth factor compositions and methods for their use
DK2253614T3 (en) IAP inhibitors
DK1778718T3 (en) IAP inhibitors
DK1748780T3 (en) Methods and related compositions for reducing fat
DK2302055T3 (en) Methods and compositions involving miRNA and miRNA inhibitor molecules
DK1789041T3 (en) Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
DK1960352T3 (en) 2-adamantylurine ingredients as selective 11beta-hsd1 inhibitors
DK1797042T3 (en) Indozolone derivatives as 11B-HSD1 inhibitors
DK2004786T3 (en) Cleaning Compositions and Methods
AT540035T (en) Spiro-2,4-pyrimidindiamine compounds and their uses
RU2007118490A (en) Enzymes
AT466933T (en) I-crei-meganuclease variants with modified specificity and method for their preparation and use
DE602004011340D1 (en) Diaryl-urea substances with chinese-inhibiting effect
AT515548T (en) Stabilized iodocaline compositions
DE502005010604D1 (en) Turbomachine
DE602005018509D1 (en) N-2-adamantanyl-2-phenoxy-acetamide derivatives as 11-betahydroxysteroid dehydrogenase inhibitors
DE602005015349D1 (en) Improved rubber-modified monovinyliden aroma-polymers and products manufactured thereof
RU2007117925A (en) Sweetener Composition